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Despite significant developments occurring in the treatment of cancer, it still remains the second deadly  
disease, responsible for 8.2 million deaths every year. Various natural substances have been studied for active molecules  
of tumor suppression in the past and the tropical flora, by its diversity, continues to provide new antitumor drugs.  
Crateva adansonii dichloromethane-methanol (DCM/MeOH) extract was previously reported to prevent breast  
tumors in Wistar rats. However, it exhibited weak cytotoxic effect in human MCF-7 cells. The present study, therefore, 
deals with the investigation of its estrogenic and antiestrogenic effects. In vitro estrogenicity and antiestrogenicity  
of C. adansonii DCM/MeOH extract were performed by E-screen assay. In vivo, the investigation was carried out using  
the 3 days uterotrophic assay in ovariectomized rats, a classical tool for the prediction of estrogenicity of chemicals.  
As a result, C. adansonii extract did not induce MCF-7 cells proliferation, which is an estrogenic hallmark. However,  
C. adansonii extract induced a significant (P <0.05) decrease in a concentration-dependent manner of the  
MCF-7 proliferation when co-administered with E2B. In vivo, no estrogen-like effect was observed following a  
3-day treatment with C. adansonii extract in estrogen target organs. However, the co-administration of C. adansonii  
extract with E2V lead to decreased uterine wet weight (P <0.05), total protein levels in uteri (P <0.01) as well as uterine and 
vaginal epithelial heights (P <0.05) as compared to animals treated with E2V only. These results suggest that C. adansonii 
has antiestrogenic effects but not estrogenic effects, which might account for its previously observed antimammary tumour 
effects in rats. 
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Estrogens are steroid hormones involved in almost all 
metabolisms (brain, cardiovascular system, kidneys, 
immune system, liver and bone) in women with an 
important function in the regulation of sex process1,2. 
Due to its ubiquitous distribution and proliferative 
effects, estrogens play an important role in the 
development and progression of estrogen dependent 
cancers. Cancer can be defined as a group of diseases 
characterized by the unregulated proliferation of 
abnormal cells that invade and disrupt surrounding 
tissues3. It is a source of significant morbidity 
worldwide, responsible for over 8.2 million deaths per 
year and a serious public health problem in both, 
developed and developing countries4. In developing 
countries including Cameroon, estrogen-dependent 
cancers (breast, uterus, and ovarian) account for  
19% of cancers worldwide and are among the  
leading causes of morbidity and mortality in these 
countries5.  
Blockage of estrogens production with specific 
inhibitors of steroidogenic enzymes such as aromatase 
inhibitors is one of the two currently available 
standard therapies. The other approach involves 
blocking the estrogen receptor (ER) with selective 
estrogen receptor modulators (SERMs) such as 
tamoxifen6,7. Although these therapies are effective to 
treat and/or prevent estrogen-dependent cancers, their 
long term use is associated with side effects and the 
therapy only reduces the risk of recurrence by  
30-50%8. Therefore, non-synthetic and natural 
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alternative, that might exert selective effects by acting 
as an estrogen receptor (ER) antagonist on neoplastic 
or normal breast and uterine tissues, and as an ER 
agonist on estrogen dependent tissues, such as bones, 
brain and liver are needed; and phytoestrogens are 
promising candidates9. Phytoestrogens are plant 
metabolites with the chemical structure shaped as that 
of 17β-estradiol and mimic estrogenic actions in 
mammals10. Since they are endowed with both 
estrogenic and antiestrogenic properties, these natural 
selective estrogen receptors modulators are now 
promoted as a preventive alternative against estrogen-
dependent cancers11.  
Based on the traditional claims, our previous work 
focused on Crateva adansonii DC (syn: Crateva 
réligiosa auct., family: Capparaceae). This plant is a 
small tree of 5-6 m high that grows in Sahelian and 
Sudanese area, including the Far-North region of 
Cameroon. It is commonly called "varun" or "garlic 
pear" in English12; "migingirgingir" in Giziga and 
"scramataihi" in Fufulde. An infusion of C. adansonii 
leaves and stem twigs is used to treat constipation and 
for intimate washing of postmenopausal women13. 
The bark is used to cure uterine affections  
and inflammatory conditions12,14. According to 
Arbonnier15, this plant is traditionally used in  
sub-Saharan Africa to treat cancer, which raised our 
interest for this plant. The DCM/MeOH extract of  
C. adansonii DC was found to prevent breast tumour 
chemically induced in Wistar rats, whereas it  
showed weak cytotoxic effect against MCF-7 cells  
(CC50 = 289 µg/mL). In addition, this extract was 
found to decrease uterus wet weight, uterine and 
vaginal epithelial heights in rat undergoing breast 
cancer investigation16. These findings suggest that the 
aforesaid extract might have estrogenic/antiestrogenic 
phytoconstituents. The UHPLC-ESI-QTOF-MS 
analysis, lead to identify citric acid ester derivatives, 
arylpropanoid, phenylpropanoid, flavane, sesquiterpene 
derivatives, gallotannin and lignans as the main 
metabolites of C. adansonii DCM/MeOH extract16.  
To the best of our knowledge, there is no published 
study investigating estrogenic/antiestrogenic activity 
of C. adansonii. To verify this hypothesis, the ability 
of Crateva adansonii DCM/MeOH extract to induce 
estrogenic and/or antiestrogenic effects in MCF-7– 
human ER+ breast cancer was tested. In vivo testing, a 
3-day uterotrophic assay in ovariectomized adult rats 
[a classical tool for the detection of estrogenicity of 
chemicals]17, was further used.  
Materials and Methods 
 
Chemicals 
The 17β-Estradiol benzoate [(Estra-1,3,5(10)-trien-
3,16α,17β-triol), purity ≥98%] was obtained from 
Sigma-Aldrich (Hamburg, Germany). Estradiol 
valerate (Progynova® 2mg) was purchased  
from DELPHARM (Lille, France). The 2-[4-(2-
hydroxyethyl)piperazin-1-yl]ethanesulfonic acid 
(HEPES, purity ≥99.5%) was purchased from Ludwig 
Biotecnologia Ltda (Alvorada, RS, Brazil). Trypan 
blue was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Fetal bovine serum (FBS) was obtained 
from Cultilab (Campinas, SP, Brazil). The cell culture 
mediums were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Serum and antibiotics were 
purchased from GIBCO (Grand Island, NY). 
Penicillin (xtapen®) was provided by CSPC 
Zhongnuo pharmaceutical (Shijiazhuang City, China). 
Diclofenac (Dicloecnu®) was provided by ECNU 
pharmaceutical (Yanzhou City, China).  
 
Plant material 
The stem barks of C. adansonii DC. (Capparaceae) 
were harvested in Moutourwa (Far-North Region of 
Cameroon) on the 16th April 2015 (pluvial season) 
around 11:00 a.m. The plant was localized at the 
geographical coordinates of 10°21’082’’ North, 
014°18’979’’ East and 472±3 m of altitude with a 
“GARMIN” Global positioning System. The sample 
used in this study was identified by Dr. Gilbert Todou 
at the National Herbarium of Cameroon in Yaounde, 
where the voucher specimens (36359/HNC) were 
registered and deposited for ready reference.  
 
Preparation of extract 
The stem barks of C. adansonii were cleaned and 
dried under shade in an aerated place. The well-dried 
stem barks of C. adansonii were pulverized by 
electronic grinding. Extract preparation were 
performed as previously described16. Briefly, 2000 g of 
powder was macerated in 5 L of DCM/MeOH mixture 
(v/v: 1/1) for 3 days at room temperature (23°C). The 
process was repeated twice and 33.18 g (1.66% of 
yield) of crude extract was obtained after filtration 
through a Whatman N°4 filter paper and evaporation of 
solvents using a rotary evaporator in vacuum under 
reduced pressure (from 875 to 337 mbar) at 40°C.  
 
In vitro experiment 
Cell line system  
The MCF-7 human ER-positive breast 
adenocarcinoma cells were obtained from the Rio de 
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Janeiro Cell Bank (Federal University of Rio de 
Janeiro, Brazil).  
 
Cell culture  
MCF-7 cells were cultured in RPMI-1640 medium 
supplemented with 10% of FBS. Cell culture was also 
supplemented with 100 U/mL penicillin, 100 µg/mL 
streptomycin and 10 mM HEPES. The cell culture 
was maintained at 37oC in a 5% CO2 humidified 
atmosphere and pH 7.4. Every two days, cells were 
passaged by removing 90% of the supernatant and 
replacing it with fresh medium. Viable cells were 
checked at the beginning of the experiment by Trypan 
Blue dye exclusion test. 
 
Cytotoxicity  
The cytotoxicity of C. adansonii DCM/MeOH 
extract was evaluated by Alamar Blue (resazurin) 
assay in MCF-7 cells. This assay evaluates the 
mitochondrial production as a measurement of cell 
viability. For this to be done, a density of 1×104 
cells/well was seeded in a 96-well plate in 100 µL of 
culture medium. After 24 h to permit their adhesion, 
cells were exposed for 24 h to the C. adansonii extract 
at concentrations ranging from 10-8 to 10-5 µg/mL. 
Experiment was performed in triplicate and repeated 
three times.  
 
E-screen assay  
Estrogenic and antiestrogenic effects of  
C. adansonii DC DCM/MeOH extract were assessed 
in vitro by a simple and sensitive E-screen cell 
proliferation assay with MCF-7 cells. This assay 
determines the estrogenicity/antiestrogenicity of 
compounds indirectly through measurement of the 
proliferation of MCF-7 cells. For this purpose, the 
technique adapted from those of Resende et al.18 was 
used. Briefly, cells were trypsinized and seeded in 24-
well plates at an initial concentration of 50000 cells 
per well in 10% FBS in RPMI. After 24 h of 
incubation (37°C, 5% CO2) to permit their adhesion, 
cells were washed with phosphate-buffered saline 
(PBS) and the Serum Replacement 2 (0.5×) 
supplemented phenol red-free RPMI was substituted 
for the seeding medium. The C. adansonii 
DCM/MeOH extract was added to the experimental 
medium at concentrations from 10-8 to 10-5 µg/mL. 
For antiestrogenicity tests, before incubation, 1×10-8 
M of 17β-estradiol was added to the wells. Steroid-
free experimental medium consisted to negative 
control while cells treated with 1×10-8 M of  
17β-estradiol served as positive control. There were 
also a solvent control (DMSO at 0.01%) and a 
medium control (10% FBS in RPMI). The assay was 
stopped after 144 h by removing the medium from 
wells, and then cells were treated with cold 10% 
trichloracetic acid and incubated at 4°C for 1 h. 
Thereafter they were washed four times with tap 
water and dried. Furthermore, cells were stained 
during 30 min with 0.057% (w/v) SRB dissolved in 
1% acetic acid. Wells were rinsed four times with 1% 
acetic acid and air dried. Bound dye was solubilized 
with 10 mM Tris base (pH 10.5) in a shaker. Finally, 
aliquots were read in a Biotek EL800 absorbance 
reader (Winoosky, USA) at 510 nm. Results 
expressing the estrogenic activity were showed as 
mean ± standard error of mean of the proliferative 
effect (PE), which represents the maximum 
proliferation induced by the compounds. This 
parameter was calculated according to Schiliro e´t al.19, 
and is the ratio between the highest cell number 
achieved with the sample or 17β-estradiol and the cell 
number in the solvent control (0.01% DMSO):  
PE = max cell number of sample/cell number of 
DMSO control. The estrogenic activity of a sample 
was determined as the relative proliferative effect 
(RPE%). The RPE compares the maximum 
proliferation induced by a sample with that induced 
by 17β-estradiol: RPE% = [PE for sample/PE for 
17β-estradiol] ×100. 
 
In vivo experiment 
Animals 
Forty five adult female Wistar rats, aged 60-70 
days at the start of experiment and weighing around 
150-170 g, were supplied by the breeding facility of 
the Laboratory of Animal Physiology, University of 
Yaounde I (Yaounde, Cameroon). Animals were 
housed in plastic cages in groups of five at room 
temperature. The animals had free access to drinking 
water and to a standard pellet rat diet. The 
composition of animal diet was: corn (36.7%), bone 
flour (14.5%), wheat (36.6%), fish flour (4.8%), 
crushed palm kernel (7.3%), sodium chloride (0.3%) 
and vitamin complex (Olivitazol® - 0.01%). Rats 
were treated in accordance with the guidelines and 
procedures of animal bioethics of the Cameroon 
National Institutional Ethic Committee (CEE Council 
86/609), which adopted all procedures recommended 
by the European Union on the protection of animals 
used for scientific purposes.  
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The 3-day uterotrophic assay  
Forty five female Wistar rats were pretreated with 
a single intramuscular dose of long acting penicillin 
and diclofenac (10 mg/kg and 3 mg/kg, respectively) 
the day before ovariectomy. Further, animals were 
bilaterally ovariectomized (OVX) using the dorsal 
approach under Diazepam and ketamin anesthesia 
(respectively 10 mg/kg and 50 mg/kg body wt.; i.p.). 
After 14 days of endogenous hormonal decline15, 
animals were randomly distributed into 9 groups of 
five animals each (n = 5). The negative control group 
(Control) was treated with the vehicle (2% ethanol). 
The positive control group received estradiol 
valerate (E2V) as standard drug at the optimal dose 
of 1 mg/kg body wt./day. One group was co-treated 
with E2V (1 mg/kg body wt.) and the pure anti-
estrogen faslodex (ICI 182,780) at the dose of  
300 µg/kg body wt./day. The remaining groups 
received DCM/MeOH extract of C. adansonii DC at 
doses of 75, 150 and 300 mg/kg body wt./day for  
3 days in presence or not of E2V (for antiestrogenic 
evaluation). All treatments were administered by 
oral route (2 mL/150 g) for 3 days. Twenty-four 
hours past last administration, animals were 
euthanized by decapitation. The uterine wet weight, 
total protein levels in uterus, uterine and vaginal 
epithelial heights and mammary gland were assessed 
as described before by Zingue et al.16.  
 
Histological analysis 
Using the complete Zeiss equipment consisting of 
a microscope Axioskop 40 connected to a computer 
where the image was transferred, and analyzed with 
the MRGrab1.0 and Axio Vision 3.1 softwares, all 
provided by Zeiss (Hallbermoos, Germany), the 
histomorphology of the mammary glands, as well as 
the uterine and vaginal epithelial heights, were 
assessed from 5-µm sections of paraffin-embedded 
tissues following hematoxylin-eosin staining. 
 
Biochemical analysis 
Total uterine protein levels were determined in uteri 
using colorimetric methods described by Gonal et al.20. 
 
Statistical analysis 
Results are presented as means ± standard error 
of mean (SEM). In vitro experiment was performed 
in triplicates and repeated three times. All formulas 
and functions were calculated with Microsoft Excel 
software. Data analysis was performed with 
GraphPad Prism 5.0 software, using the ANOVA 
test followed by the Dunnett’s post hoc test. 
Differences were considered significant at a 
probability level of 5% (P <0.05). 
 
Results 
 
In vitro experiments 
 
Cytotoxicity 
C. adansonii DCM/MeOH extract did not induced 
cytotoxic effects in MCF-7 cells at concentrations 
range between 10-8 and 10-5 µg/mL (Fig. 1A). 
 
E-screen assay 
Figure 1B depicts effects of C. adansonii extract in 
MCF-7 cells proliferation. It can be observed that 
E2B induced a significant (P <0.001) increased of 
MCF-7 cells yield. C. adansonii extract did not induce 
MCF-7 cells proliferation as compared to DMSO 
control. However, a significant and concentration-
dependant inhibition of cells proliferation, meaning 
antiestrogenic effect was noted with C. adansonii 
extract when co-treated with E2B. 
 
In vivo experiments 
Effects on uterus 
A 3-day treatment with E2V (1 mg/kg) 
significantly (P <0.001) increased uterine wet weight, 
uterine epithelium height as well as uterine total 
protein level as compared to the negative control 
group (OVX) (Fig. 2). The co-treatment of faslodex 
with estradiol (E2V) significantly reduced total 
 
 
Fig. 1 — Effects of Crateva adansonii extract on MCF-7 cells 
proliferation. Its effect was investigated by measuring E-screen 
assay. [The relative MCF-7 cells yields (PE) were measured in the 
presence of DMSO (0.01%), 17β-estradiol (E2B, 10 nM) and 
CA = C. adansonni DCM/MeOH extract. PE = max cell number 
of sample/cell number of DMSO control. * P <0.05, *** P <0.001 
as compared to the DMSO control] 
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protein level (P <0.01), uterine wet weight (P <0.001) 
and uterine epithelium height (P <0.001) as compared 
to the positive control group (E2V). C adansonii 
DCM/MeOH extract did not induce any changes in 
uterine parameters at all tested doses compared to 
OVX control group. However, when combined with 
E2V, it was observed a significant (P <0.05) 
reduction of uterine wet weight at doses of 75 and  
150 mg/kg, total protein level in uterus at doses of  
75 and 300 mg/kg; while only the dose of 75 mg/kg 
significantly (P <0.01) reduced uterine epithelium 
height as compared to E2V group (Fig. 2). 
 
Effects on vagina 
Fig. 3 depicts the microphotographs of vagina 
obtained after a 3-day treatment with C. adansonii 
DCM/MeOH extract. As expected, E2V treatment 
induced a significant increase (P <0.001) of vaginal 
epithelium height as compared to OVX group.  
C. adansonii extract failed to alter vaginal epithelium 
height at all tested doses. However, when combined 
with the E2V, it was noted a significant (P <0.01) 
reduction of this parameter at the dose of 75 mg/kg. 
 
Effects on mammary glands 
Fig. 4 shows microphotographs of mammary 
glands obtained after a 3-day treatment with  
C. adansonii DCM/MeOH extract. E2V treatment 
increased the size of the acini as well as epithelial 
cells of the acini, and there is also an abundant 
eosinophile secretions inside the acini. Faslodex 
 
 
Fig. 3 — Effects of a 3 day treatment with C. adansonni 
DCM/MeOH extract on the vaginal epithelium: (A) micro-
photographs; and (B) epithelial height. [OVX = OVX animals 
treated with the vehicle; E2V = OVX animals treated with estradiol 
valerate at 1 mg/kg body wt.; E2V + FAS = OVX animals 
co-treated with E2V at 1 mg/kg body wt. and faslodex (300 µg/kg); 
CA = OVX animals treated with C. adansonni DCM/MeOH extract
at doses of 50, 150 and 300 mg/kg body wt.; and CA + E2V = OVX 
animals co-treated with C. adansonni DCM/MeOH extract at doses 
of 50, 150 and 300 mg/kg body wt. and E2V (1 mg/kg). 
Lv = vaginal lumen; Co = stratum corneum; Gr = stratum 
granulosum; Ge = stratum germinativum; St= Stroma] 
 
 
Fig. 2 — Effects of a 3-day treatment with C. adansonni DCM/MeOH extract on (A) the uterine wet weight; (B) total protein levels in 
uterine; (C) uterine epithelial height; (D) and microphotographs. [OVX = OVX animals treated with the vehicle; E2V = OVX animals 
treated with estradiol valerate at 1 mg/kg body wt.; E2V + FAS = OVX animals co-treated with E2V at 1 mg/kg body wt. and faslodex 
(300 µg/kg); CA = OVX animals treated with C. adansonni DCM/MeOH extract at doses of 50, 150 and 300 mg/kg body wt.; and CA + 
E2V = OVX animals co-treated with C. adansonni DCM/MeOH extract at doses of 50, 150 and 300 mg/kg body wt. and E2V (1 mg/kg). 
*P <0.05, **P <0.01 as compared with control. Lu = uterine lumen; En = Endometrium; St = Stroma] 
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inhibited estrogenic effect by reducing the  
acini height, as well as the eosinophile secretions  
in acini. No estrogenic-like effect was noted with  
C. adansonii treatment in this parameter. However,  
it counteracted the effects of E2V in mammary  
glands by reducing the acini heights and  
eosinophile secretion in acini when co-administered 
with E2V. 
 
Discussion 
In certain regions of the world, particularly in Asia, 
a low incidence of breast cancer has been observed. 
These women have diets that are high in soy and low 
in fat21. These soy beneficial effects have been attributed 
to phytoestrogens, which are plant derivatives that 
bear a structural similarity to 17-β estradiol and act in 
a similar manner. In our previous work, Crateva 
adansonii extract prevented breast tumours induced in 
rat and significantly reduced the uterine wet weight as 
compared to both normal and tumour groups at the 
dose 75 mg/kg16. In order to contribute to a better 
underlying mechanism of this plant constituents,  
its estrogenic/antiestrogenic effects were assessed.  
C. adansonii extract counteracted MCF-7 cells 
proliferation induced by E2V using E-creen  
assay. This assay, initially used by Soto et al.22 
compares cell proliferation after estradiol  
treatment that yield by tested substances.  
Resende et al.18 reported that a relative  
proliferative effect (RPE) ≥80 corresponds to 
estrogenic activity and suggest that the compound 
may have agonistic activity through ERα. No MCF-7 
cells proliferation was observed with C. adansonii, 
while a concentration-dependent decrease of the  
E2-induced cell proliferation was observed when this 
extract was co-administered with E2 as compared to 
E2 treatment only. This result suggests that  
C. adansonii might contain compounds that may enter 
in competition with ERs and collect the corepressors 
responsible for antiestrogenic effects23. In vivo  
C. adansonii extract failed to induce estrogenic effect, 
however   it   counteracted  E2-induced  increased  in  
uterine wet weight, uterine and vaginal epithelial 
height. These results suggest that C. adansonii  
extract could have secondary metabolites with 
antiestrogenic properties, which in turn can  
account for its antitumour effects. Antiestrogenic 
effects are a needed effect on estrogen-dependent 
breast cancer, which are approximately two thirds of 
all breast cancers. C. adasonnii extract exerts 
beneficial breast cancer preventive action by 
competing with endogenous estrogen, thus limiting 
the mammary gland ductal and lobular proliferation. 
Flavane and flavonol (quercetin) detected in this 
extract in our previous report16, are well known  
as phytoestrogens. Just like SERMS, phytoestrogens 
can bind to either ERα or ERβ however; 
phytoestrogens appear to have a higher affinity  
for ERβ24. This affinity may be dose-dependent  
but overall phytoestrogens have a significantly  
lower affinity for the ER than estradiol25. Indeed, it 
has been found that at a concentration 100 to  
1000 times higher than estradiol, phytoestrogens  
enter in competition with endogenous estrogens  
for ERs by preventing estrogens stimulated growth  
in mammals26. Since MCF-7 cells can elicit 
estrogenic/antiestrogenic responses involving  
both genomic and non-genomic pathways19; it can be 
hypothesized that phytoestrogens detected in  
C. adansonii DCM/MeOH extract might modulate 
endogenous estrogens concentration by linking or 
inactivating some enzymes which can influence 
bioavailability of sex hormone binding globulin 
and/or enter in competition with E2 for ERs27. 
 
 
Fig. 4 — Effects of a 3-day treatment with C. adansonni 
DCM/MeOH extract on mammary gland. [OVX = OVX animals 
treated with the vehicle; E2V = OVX animals treated with 
estradiol valerate at 1 mg/kg body wt.; E2V + FAS = OVX 
animals co-treated with E2V at 1 mg/kg body wt. and faslodex 
(300 µg/kg); CA = OVX animals treated with C. adansonni 
DCM/MeOH extract at doses of 50, 150 and 300 mg/kg body wt.; 
and CA + E2V = OVX animals co-treated with C. adansonni 
DCM/MeOH extract at doses of 50, 150 and 300 mg/kg body wt. 
and E2V (1 mg/kg).  La = lumen of alveoli; Ep = aveoli 
epitheluim; At = adiposite tissue; Se = eosinophil secretion] 
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Conclusion 
C. adansonii extract is now reported to endow 
antiestrogenic effects. This might account to  
its antitumour activity. Flavonoids detected in  
this extract may be the key compounds that exert  
this activity. In depth investigations are needed to 
isolate and assess the affinity as well as the ability of 
these compounds to transactivate the estrogen 
receptors. 
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